Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-95437446 in Advanced-Stage Solid Tumors
NCT07107230Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2025
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of JNJ-95437446 in non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC) and head and neck squamous cell carcinoma (HNSCC), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events by Severity and Number of Participants with Dose-Limiting Toxicity up to 21 days. Started Jul 2025; status: recruiting.
02
Drugs
JNJ-95437446
03
Conditions
non-small cell lung cancer (NSCLC)colorectal carcinoma (CRC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07107230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07107230.